首页> 外国专利> COMBINATION OF DOSING AMOUNTS OF A PHARMACEUTICAL PREPARATION FOR TREATING CANCER IN HUMAN, USE OF THE DOSING AMOUNT OF A MEDICAMENT AGAINST CANCER AND HYALURONIC ACID AND PHARMACEUTICAL PREPARATIONS

COMBINATION OF DOSING AMOUNTS OF A PHARMACEUTICAL PREPARATION FOR TREATING CANCER IN HUMAN, USE OF THE DOSING AMOUNT OF A MEDICAMENT AGAINST CANCER AND HYALURONIC ACID AND PHARMACEUTICAL PREPARATIONS

机译:用于治疗人类癌症的药物制剂的给药量的组合,使用抗癌药物的剂量以及透明质酸和药物制剂

摘要

A new method for the treatment of cancer in a human particularly malignant tumors, for example those in a breast or breasts, said method comprising the steps of: (1) directly injecting into the tumour a dosage amount of a pharmaceutical composition comprising an effective amount of an anti-cancer drug and/or drug suitable for use to treat cancer (for example about 1 to about 2 mg NovantroneTM (Mitoxantrone), other chemotherapeutic agent, NSAIDs) and an effective amount of a form of hyaluronic acid, for example hyaluronic acid and/or pharmaceutically acceptable salts thereof preferably sodium hyaluronate having a molecular weight of less than 750,000 daltons (for example 150,000 - 225,000 daltons) (for example about 10 to about 20 mg sodium hyaluronate) in sterile water; and (2) administering systemically, preferably intravenously, a dosage amount of a pharmaceutical composition comprising: (i) an effective amount of a form of hyaluronic acid (for example hyaluronic acid and/or pharmaceutically acceptable salts thereof, preferably sodium hyaluronate having a molecular weight less than 750,000 daltons (for example 150,000 - 225,000 daltons) for example about 100 - 200 mg or more (because of a lack of toxicity and to reduce the side effects of any medicine (for example NSAID) administered therewith if the amount of the form of hyaluronic acid exceeds about 200 mg/70 kg person); (ii) a drug selected from the group comprising: a) a non-steroidal anti-inflammatory drug (NSAID) for example in an amount of from about 30 mg to about 100 mg (for example 30 to 60 mg of tromethanine salt of ketoralac (sold under the trade mark Toradol) and 50 to 100 mg of diclofenac or diclofenac sodium (for example sold under the trade mark Voltarol), b) an anti-cancer drug, and c) a drug suitable for use to treat cancer and combinations thereof optionally together with (iii) an anti-oxidant for example Vitamin C (in one embodiment 25 gm of Vitamin C).
机译:一种用于治疗人类特别是恶性肿瘤(例如乳房或胸部肿瘤)中的癌症的新方法,所述方法包括以下步骤:(1)将一定剂量的包含有效量的药物组合物直接注入肿瘤中抗癌药和/或适用于治疗癌症的药物(例如约1至约2毫克NovantroneTM(米托蒽醌),其他化学治疗剂,NSAIDs)和有效量的透明质酸,例如透明质酸和/或其药学上可接受的盐,优选在无菌水中具有小于750,000道尔顿(例如150,000至225,000道尔顿)(例如约10至约20mg透明质酸钠)的分子量的透明质酸钠; (2)全身,优选静脉内给药一定剂量的药物组合物,其包含:(i)有效量的透明质酸形式(例如透明质酸和/或其药学上可接受的盐,优选具有分子结构的透明质酸钠)。小于750,000道尔顿(例如150,000-225,000道尔顿)的体重,例如约100-200 mg或更多(由于缺乏毒性并减少与之一起服用的任何药物(例如NSAID)的副作用)透明质酸的形式超过约200毫克/ 70千克人);(ii)选自以下的药物:a)非类固醇抗炎药(NSAID),例如约30毫克至约70毫克100毫克(例如ketoralac的氨丁三醇盐30至60毫克(以Toradol商标出售)和50到100毫克的双氯芬酸或双氯芬酸钠(例如以Voltarol商标出售),b)抗癌药和c)适用于治疗癌症的药物及其组合,任选地与(iii)抗氧化剂,例如维生素C(在一个实施方案中为25克维生素C)。

著录项

  • 公开/公告号CZ308996A3

    专利类型

  • 公开/公告日1998-01-14

    原文格式PDF

  • 申请/专利权人 HYAL PHARMACEUTICAL CORPORATION;

    申请/专利号CZ19960003089

  • 发明设计人 FALK RUDOLF EDGAR;ASCULAI SAMUEL SIMON;

    申请日1995-04-28

  • 分类号A61K31/725;A61K31/19;A61K31/70;A61K31/495;

  • 国家 CZ

  • 入库时间 2022-08-22 02:58:24

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号